Japan’s MHLW And Baxter In Talks To Bring New Flu Vaccines To Japan
This article was originally published in PharmAsia News
Executive Summary
U.S. major drug maker Baxter International June 16 disclosed that the company is talking with Japan's Ministry of Health, Labor and Welfare about exporting new H1N1 flu vaccines to Japan. Baxter said a negotiation toward signing a supply contract with the MHLW is ongoing and the first shipment could be ready as early as July. Currently, four Japanese domestic vaccine makers including Kitazato Institute are preparing to manufacture flu vaccines for the new H1N1 flu virus; however, due to limited production capability, the MHLW has been actively looking for additional supplies from overseas vaccine makers. Using cell engineering technology rather than the conventional egg method, Baxter is capable of producing a large amount of H1N1 vaccine in a shorter period of time. Baxter plans a July shipment, and could supply the world's first H1N1 vaccines ahead of Novartis. (Click here for more - Japanese Language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.